Change in Lp-PLA2 With Risk Change on Statin Therapy in the Collaborative Atorvastatin Diabetes Study (CARDS)

Change in Lp-PLA2 With Risk Change on Statin Therapy in the Collaborative Atorvastatin Diabetes Study (CARDS)

Bibliographic Details
Main Authors:	Betteridge, D, Colhoun, H, Durrington, P, Hitman, G, Neil, H, Livingstone, S, Bao, W, DeMicco, D, Preston, G, Fuller, J, Investigators, CARDS
Format:	Conference item
Published:	2009

Similar Items

Effect of atorvastatin in patients 65 years of age with type 2 diabetes: Subgroup analysis from the collaborative atorvastatin diabetes study (CARDS)
by: DeMicco, D, et al.
Published: (2005)

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
by: Colhoun, H, et al.
Published: (2009)

Effect of atorvastatin on stroke in patients with type 2 diabetes: factors predicting the risk of stroke in the Collaborative Atorvastatin Diabetes Study (CARDS)
by: Hitman, G, et al.
Published: (2005)

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
by: Charlton-Menys, V, et al.
Published: (2009)

Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
by: Neil, H, et al.
Published: (2006)

Safety of atorvastatin in the collaborative AtoRvastatin diabetes study (CARDS)
by: Newman, C, et al.
Published: (2006)

Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
by: Colhoun, H, et al.
Published: (2005)

Erratum: Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: The Collaborative Atorvastatin Diabetes Study (CARDS)
by: Charlton-Menys, V, et al.
Published: (2009)

The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS).
by: Newman, C, et al.
Published: (2008)

Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).
by: Charlton-Menys, V, et al.
Published: (2009)

Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).
by: Hitman, G, et al.
Published: (2007)

Effect of atorvastatin on stroke in the collaborative atorvastatin diabetes study (CARDS): Factors predictive of the risk of stroke
by: Newman, C, et al.
Published: (2005)

C-reactive Protein and Amyloid A as Predictors of Cardiovascular Events in Type 2 Diabetes in CARDS
by: Charlton-Menys, V, et al.
Published: (2009)

Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
by: Thomason, M, et al.
Published: (2004)

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
by: Colhoun, H, et al.
Published: (2004)

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).
by: Raikou, M, et al.
Published: (2007)

Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.
by: Colhoun, H, et al.
Published: (2002)

Cost-effectiveness of atorvastatin (10mg) in patients with type 2 diabetes without coronary heart disease: CARDS trial analysis and extrapolation
by: Raikou, M, et al.
Published: (2005)

The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease
by: Soedamah-Muthu, S, et al.
Published: (2011)

Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial.
by: Colhoun, H, et al.
Published: (2011)

The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
by: Soedamah-Muthu, S, et al.
Published: (2003)

Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes
by: Deedwania, PC, et al.
Published: (2016)

STATINS AND PERCUTANEOUS CORONARY INTERVENTION. FOCUS ON THE ATORVASTATIN
by: N. G. Gogolashvili
Published: (2015-09-01)

STATINS AND PERCUTANEOUS CORONARY INTERVENTION. FOCUS ON THE ATORVASTATIN
by: N. G. Gogolashvili
Published: (2015-09-01)

The V279F polymorphism might change protein character and immunogenicity in Lp-PLA2 protein
by: Widodo, et al.
Published: (2018-04-01)

Statines in treatment of patients with diabetes mellitus: niche of atorvastatine
by: S. A. Urazgildeeva
Published: (2018-03-01)

Unraveling the PAF-AH/Lp-PLA2 controversy1
by: Diana M. Stafforini, et al.
Published: (2014-09-01)

Changes and significance of serum monocyte chemoattractant protein-1 and Lp-PLA2 in patients with hypertension and coronary heart disease
by: Yongbo Tian, et al.
Published: (2022-02-01)

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy
by: Foody JM, et al.
Published: (2013-11-01)

Pleiotropic effects of statins at the present stage of their study (focus on atorvastatin). Part III. Mechanisms of the pleiotropy of statins
by: D. M Aronov
Published: (2013-06-01)

Relationship between atorvastatin dose and the harm caused by torcetrapib
by: Philip J. Barter, et al.
Published: (2012-11-01)

Pharmacogenetic Approaches to Enhancing Efficacy and Safety of Statins as Illustrated by the Example of Atorvastatin
by: R. Ye. Kazakov, et al.
Published: (2020-03-01)

Antibacterial activity of statins: a comparative study of Atorvastatin, Simvastatin, and Rosuvastatin
by: Masadeh Majed, et al.
Published: (2012-05-01)

Statin therapy and hepatotoxicity: Appraisal of the safety profile of atorvastatin in hyperlipidemic patients
by: Saeed Kalantari, et al.
Published: (2014-01-01)

Expression of hTERT and Lp-PLA(2) genes is increased in primary hypothyroidism.
by: Seema Garg, et al.
Published: (2024-06-01)

Amstirdam coffee ameliorates Lp-PLA2 and the inflammatory response in an atherosclerosis rats
by: Wirdatun Nafisah, et al.
Published: (2024-01-01)

Lp-PLA2 as a promising predictor of comorbidities in patients with severe psoriasis
by: Paulina Kiluk, et al.
Published: (2020-07-01)

Influencing factors of serum Lp-PLA2 level in patients with diabetic retinopathy
by: Zhao-Hui Hui, et al.
Published: (2018-12-01)

Relationship of High‐Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin
by: Kwok Leung Ong, et al.
Published: (2018-01-01)

Higher serum Lp-PLA2 is associated with cognitive impairment in Parkinson’s disease patients
by: Zubo Wu, et al.
Published: (2024-03-01)